Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 6Breast Neoplasms 2Small Cell Lung Carcinoma 1Recurrence 1Prostate Cancer Metastatic 1Neoplasm Metastasis 1Metastatic Breast Cancer With Intracranial Metastases 1Lung Neoplasms 1Hormone-Resistant Prostate Cancer 1Diarrhea 1Castrate-resistant Metastatic Prostate Cancer 1Carcinoma, Transitional Cell 1Brain Neoplasms 1

Interventions

Octreotide 2telotristat ethyl 1isatuximab 1ceterizine hydrochloride 1capivasertib 1cabazitaxel 1XRP6258 1Prednisone 1Loperamide 1Leucovorin 1Lapatinib 1Irinotecan 1Injections 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Fluorouracil 1Filgrastim 1Drugs, Investigational 1Cyclophosphamide 1Colesevelam Hydrochloride 1Cell- and Tissue-Based Therapy 1Capecitabine 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Diarrhea × XRP6258 × Clear all
NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡